<DOC>
	<DOCNO>NCT00040677</DOCNO>
	<brief_summary>ICA-17043 develop chronic treatment patient sickle cell disease ( SCD ) adults child . ICA-17043 potent specific inhibitor channel human red blood cell ( RBCs ) block RBC dehydration . ICA-17043 expect inhibit RBC dehydration thus prevent delay sickling process . By reduce sickled cell , improvement anemia , reduction painful crisis , ultimately , less end-organ disease anticipate .</brief_summary>
	<brief_title>A Study Efficacy Safety ICA-17043 ( With Without Hydroxyurea ) Patients With Sickle Cell Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Homozygous ( HbSS ) Sickle Cell Anemia Otherwise healthy ( base medical history , physical examination , 12lead ECG , clinical laboratory test ) Patients may receive hydroxyurea , must dose stabilize least 3 month Patient history least one acute vasoocclusive event require hospitalization Patient participate chronic transfusion program Patient total hemoglobin &lt; 4.0 g/dL &gt; 10.0 g/dL Patient HbA &gt; 10 % Patient consider undergo elective surgery Patient take prohibited medication Epoetin , Warfarin , etc . Patient previous gastrointestinal surgery , except cholecystectomy appendectomy Patient significant active cardiovascular , neurologic , endocrine , hepatic , renal disorder unrelated sickle cell anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>sickle cell anemia</keyword>
	<keyword>sickle cell disease</keyword>
	<keyword>anemia</keyword>
	<keyword>ICA-17043</keyword>
	<keyword>senicapoc</keyword>
</DOC>